The portfolio's return was 5.34% (net) for the reporting period. We initiated the following position

BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript

Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicine

Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plas

BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

First-quarter results were broadly in line with expectations, supported by strong growth in the Biop

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

https://www.grifols.com/en/view-news/-/news/grifols-increases-q1-2026-revenues-by-3-3-to-1-7billion-

Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) a

U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market

https://www.bloomberg.com/news/articles/2026-04-02/grifols-canadian-license-restricted-after-plasma-

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada

Healthcare ​company Grifols ‌said ​on ​Tuesday it ⁠has ​approved ​a U.S. ​initial ​public offering o

Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a gl

TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press

WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manit

Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR ta

Diversify Wealth Management LLC bought a new position in Grifols, S.A. (NASDAQ: GRFS) during the und

Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript

Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) f

https://www.grifols.com/en/view-news/-/news/grifols-reports-revenues-of-eur-7524m-up-7-and-more-than

Grifols (NASDAQ: GRFS - Get Free Report) is projected to issue its Q4 2025 results before the market

CORRECTION: JP Morgan analyst Richard Vosser maintains Grifols (NASDAQ:GRFS) with a Neutral and main

JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and lowers the pric

JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and raises the pric

https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D

https://www.grifols.com/en/view-news/-/news/thomas-glanzmann-to-retire-as-grifols-chairman-and-will-

https://www.bloomberg.com/news/articles/2024-12-02/grifols-shareholder-mason-capital-calls-for-board

Grifols ends acquisition talks with Brookfield over valuation concerns, highlights strong revenue gr

https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brook

https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-dea

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effec

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six

Brookfield Asset Management is reportedly pursuing €9.5 billion in debt financing for a potential ta

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally c